Table 2.
Underlying comorbidities of the study population.
| Underlying Medical Conditions | Thal, n (%) | SCD, n (%) |
|---|---|---|
| [N = 84] | [N = 162] | |
| None | 23 (27.4) | 64 (39.5) |
| Hematology | ||
| Vaso-occlusive crisis | N/A | 69 (42.6) |
| Splenectomy | 49 (58.3) | 6 (3.7) |
| Cardiology | ||
| Hypertension | 2 (2.4) | 12 (7.4) |
| Pulmonary hypertension | 12 (14.3) | 0 (0) |
| Heart Failure | 8 (9.5) | 0 (0) |
| Cardiomyopathy | 5 (6.0) | 1 (0.6) |
| Arrhythmia | 1 (1.2) | 1 (0.6) |
| Not specified | 1 (1.2) | 0 (0) |
| Respiratory | ||
| Asthma | 2 (2.4) | 9 (5.6) |
| Pulmonary embolism | 0 (0) | 3 (1.9) |
| Obstructive sleep apnea | 1 (1.2) | 1 (0.6) |
| Chronic obstructive pulmonary disease | 0 (0) | 1 (0.6) |
| Sarcoidosis | 1 (1.2) | 0 (0) |
| Concurrent pulmonary tuberculosis | 0 (0) | 1 (0.6) |
| Not specified | 1 (1.2) | 0 (0) |
| Endocrinology | ||
| Diabetes mellitus | 19 (22.6) | 10 (6.2) |
| Hypogonadism | 20 (23.8) | 0 (0) |
| Obesity | 1 (1.2) | 13 (8.0) |
| Hypothyroidism | 9 (10.7) | 0 (0) |
| Hypoparathyroidism | 6 (7.1) | 0 (0) |
| Growth failure | 3 (3.6) | 0 (0) |
| Orthopedics | ||
| Osteoporosis | 41 (48.8) | 0 (0) |
| Avascular necrosis | 0 (0) | 2 (1.2) |
| Hepatobiliary | ||
| Chronic liver disease | 14 (16.7) | 0 (0) |
| Hepatitis | 10 (11.9) | 0 (0) |
| Gallstone disease | 1 (1.2) | 0 (0) |
| Nephrology | ||
| Chronic kidney disease / end stage renal failure | 8 (9.5) | 2 (1.2) |
| Vascular | ||
| Venous thromboembolism | 0 (0) | 7 (4.3) |
| Recurrent leg ulcer | 0 (0) | 2 (1.2) |
| Neurology | ||
| Stroke | 0 (0) | 6 (3.7) |
| Transient ischemic attack | 0 (0) | 1 (0.6) |
| Moya Moya syndrome | 0 (0) | 1 (0.6) |
| Oncology | ||
| Non-Hodgkin lymphoma | 1 (1.2) | 0 (0) |
| Acute lymphoid leukemia | 1 (1.2) | 0 (0) |
| Not specified | 0 (0) | 5 (3.1) |
| Ophthalmology | ||
| Retinopathy | 0 (0) | 2 (1.2) |
| Psychiatry | ||
| Not specified | 0 (0) | 1 (0.6) |
SCD, sickle cell disease; Thal, thalassemia; N, number; N/A, not applicable.